Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cellectar Biosc (CLRB)

1.355   -0.015 (-1.09%) 08-13 16:00
Open: 1.35 Pre. Close: 1.37
High: 1.405 Low: 1.34
Volume: 534,857 Market Cap: 36M
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.403 - 1.411 1.411 - 1.418
Low: 1.32 - 1.331 1.331 - 1.339
Close: 1.346 - 1.362 1.362 - 1.374

Technical analysis

as of: 2020-08-13 4:32:44 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 1.82     One year: 2.02
Support: Support1: 1.28    Support2: 1.06
Resistance: Resistance1: 1.56    Resistance2: 1.73
Pivot: 1.43
Moving Average: MA(5): 1.38     MA(20): 1.43
MA(100): 1.41     MA(250): 1.79
MACD: MACD(12,26):     Signal(9): 0.01
Stochastic oscillator: %K(14,3): 20.37     %D(3): 23.83
RSI: RSI(14): 44.92
52-week: High: 3.33  Low: 1.01  Change(%): -37.8
Average Vol(K): 3-Month: 127484  10-Days: 70681

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CLRB has closed above bottom band by 25.8%. Bollinger Bands are 33.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 11 Aug 2020
Cellectar Biosciences (CLRB) Gets a Buy Rating from H.C. Wainwright - Smarter Analyst

Mon, 10 Aug 2020
Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update - GlobeNewswire

Tue, 04 Aug 2020
Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting - GlobeNewswire

Fri, 31 Jul 2020
Cellectar Biosciences Inc. (CLRB) went up 21.17% yesterday: Is this the Most Sought-After Stock Today? - News Daemon

Thu, 30 Jul 2020
Is a Correction Looming Ahead? Cellectar Biosciences, Inc. (CLRB) - The News Heater

Fri, 24 Jul 2020
Is Cellectar Biosciences Inc (CLRB) Stock a Good Buy on Friday? - InvestorsObserver

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 24
Shares Float (M) 8
% Held by Insiders 2.58
% Held by Institutions 29.70
Shares Short (K) 93
Shares Short P. Month (K) 1,010

Stock Financials

EPS -1.634
EPS Est This Year -0.920
EPS Est Next Year -0.870
Book Value (p.s.) 0.440
Profit Margin
Operating Margin
Return on Assets (ttm) -84.9
Return on Equity (ttm) -191.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.595
Qtrly Earnings Growth
Operating Cash Flow (M) -12
Levered Free Cash Flow (M) -7

Stock Valuations

PE Ratio -0.83
PEG Ratio
Price to Book value 3.08
Price to Sales
Price to Cash Flow -2.62

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.